



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Philip O. Livingston and

Govindaswami Ragupathi

Serial No. : 09/534,711

Filed : March 24, 2000

For : FUCOSYL GM1-KLH CONJUGATE VACCINE AGAINST

SMALL CELL LUNG CANCER

1185 Avenue of the Americas New York, New York 10036

June 25, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22312-1450 Mail Stop OIPE

Sir:

COMMUNICATION TO CORRECT ERROR IN FILING RECEIPT

This Communication is filed to request the issuance of a corrected Filing Receipt in connection with the above-identified application. Upon receipt of the official Filing Receipt for the subject application, a copy of which is attached hereto as **Exhibit A**, applicants' undersigned attorney noticed an error.

Specifically, under Domestic Priority data as claimed by applicant, there is an indication that the data provided by applicant is inconsistent with PTO records.

A corrected filing receipt should read as follows:

--Domestic Priority data as claimed by applicant

This application is a CON of PCT/US98/20073 09/25/1998

Which is a CIP of 60/059,664 09/25/1997

Applicants contend that the correct data may be found in the Declaration and Power of Attorney and the Preliminary Amendment,

Applicants

Philip O. Livingston and

Govindaswami Ragupathi

Serial No.

09/534,711

Filed

March 24, 2000

Page 2

both filed on March 24, 2000 with the subject application. Copies of the Declaration and Power of Attorney and the Preliminary Amendment are attached hereto as Exhibits B and C, respectively. Accordingly, applicants request that a corrected Filing Receipt be issued.

No fee is deemed necessary in connection with the filing of this However, if any fee is required, authorization is Communication. hereby given to charge the amount of any such fee to Deposit Account 03-3125.

Respectfully submitted,

hereby. certify that correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope Commissioner addressed to: Patents, P.O. Box 1450, Alexandria, VA 22313-1450

60126 13

Red. No. 28,678

Date

John P. White

Registration No. 28,678 Attorney for Applicants Cooper & Dunham LLP 1185 Avenue of the Americas New York, New York 10036 (212) 278-0400



Applicant	Philip O.	Livingston et al.
Client	MSK (1747)	File NO - A-PCT-US ANT PW/FHB
Date	June 25, 2003	Ally.

Kindly acknowledge receipt of the accompanying

Communication To Correct Error In Filing Receipt in connection with Philip O. Livingston and Govindaswami Ragupathi, Fucosyl GM1-KLH Conjugate Vaccine Against Small Cell Lung Cancer, U.S. Serial No. 09/534,711, filed March 24, 2000, including Exhibit A (copy of official Filing Receipt), Exhibit B, (copy of Declaration and Power of Attorney), and Exhibit C (copy of Preliminary Amendment) and a Certificate of Mailing dated June 25, 2003.

by placing your receiving date stamp hereon and returning to us.



John P White

Cooper & Dunham LLP 1185 Avenue of the Americas

New York, NY 10036

MAR 1 5 2004

United States Patent and Brademark Office UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.C. DOI 1450 Alexandra, Virginia 22313-1450 www.maplu.gov

OC000000010185049*

APPLICATION NUMBER **FILING DATE** GRP ART UNIT FIL FEE REC'D ATTY.DOCKET.NO DRAWINGS TOT CLAIMS IND CLAIMS 53437-A-09/534,711 \ 03/24/2000 1642 345 PCT-16 US/JPW/JL

CONFIRMATION NO. 2601 CORRECTED FILING RECEIPT

Date Mailed: 06/04/2003

Receipt is acknowledged of a CPA in this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Philip O Livingston, New York, NY; \(\) Govindaswami Ragupathi, New York, NY;

Domestic Priority data as claimed by applicant

This application is a CON of PCT/US98/20073 09/25/1998 * which is a CIP of 60/059,664 09/25/1997 (*)Data provided by applicant is not consistent with PTC records.

Foreign Applications

If Required, Foreign Filing License Granted: 06/13/2000

CPA filed on: 04/21/2003

Projected Publication Date: 09/11/2003

Non-Publication Request: No

Early Publication Request: No

"* SMALL ENTITY **



Title

Fucosyl gm1-klh conjugate vaccine against small cell lung cancer v

Preliminary Class

424

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (i)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).